SCHEMBL19925815

SCHEMBL19925815

O=c1cc(CCO)oc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.69
CYP11B1 P15538 2/20 0.55
CYP11B2 P19099 2/20 0.55
KDM4E B2RXH2 2/20 0.51
USP2 O75604 1/20 0.51
CSNK2A2 P19784 1/20 0.51
PTGS1 P23219 1/20 0.51
CSNK2B P67870 1/20 0.51
CSNK2A1 P68400 1/20 0.51
CSNK2A3 Q8NEV1 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
NPC1 O15118 2/20 0.49
TNKS O95271 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PLA2G2A P14555 1/20 0.49
PLA2G4A P47712 1/20 0.49
GABRP O00591 1/20 0.49
GABRD O14764 1/20 0.49
CA12 O43570 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7596849 0.87 PPARG (0.61) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL28422971 0.87 PPARG (0.61) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL3395103 0.86 PPARG (0.63) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL29802950 0.86 PPARG (0.63) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL292258 0.83 PPARG (0.69) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL3715533 0.83 PPARG (0.69) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL30694898 0.83 PPARG (0.69) PPARGCYP11B1CYP11B2KDM4EUSP2
SCHEMBL27484451 0.82 PPARG (0.68) PPARGCYP11B1CYP11B2KDM4EUSP2
Flidersiachromone SCHEMBL5826185 0.81 PPARG (1.00) PPARGCYP11B1CYP11B2KDM4EUSP2
Flidersiachromone SCHEMBL29408800 0.81 PPARG (1.00) PPARGCYP11B1CYP11B2KDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612391-B2 Cromolyn derivatives and uses thereof THE GENERAL HOSPITAL CORPORATION (US) 2026-04-28 US disclosed
US-20240082207-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION 2024-03-14 US disclosed
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF THE GENERAL HOSPITAL CORPORATION 2024-02-29 US disclosed
CN-116889562-A Macrophage/microglial cell in neuroinflammation related to neurodegenerative diseases 通用医疗公司 2023-10-17 CN disclosed
EP-3506894-B1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES MASSACHUSETTS GEN HOSPITAL (US) 2023-08-23 EP disclosed
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2023-06-20 US disclosed
CN-109922800-B Macrophage/microglial cell in neuroinflammation related to neurodegenerative diseases 通用医疗公司 2023-06-13 CN disclosed
WO-2022146914-A1 CROMOLYN DERIVATIVES AND USES THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2022-07-07 WO disclosed
US-20220079914-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION 2022-03-17 US disclosed
EP-3506894-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES The General Hospital Corporation (US) 2019-07-10 EP disclosed
CN-109922800-A Macrophages/Microglia in Neuroinflammation Associated with Neurodegenerative Diseases 通用医疗公司 2019-06-21 CN disclosed
WO-2018045217-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION (US) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF PRNP, HTT, CLN6 PPARG 2167/4885CYP11B1 1594/4885CYP11B2 1717/4885
US-12612391-B2 Cromolyn derivatives and uses thereof HTT, PRNP, PSEN1 PPARG 3107/4885CYP11B1 2682/4885CYP11B2 2228/4885
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases CD68, PRNP, HTT PPARG 833/4885CYP11B1 3114/4885CYP11B2 3394/4885
US-20220079914-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES CD68, PRNP, HTT PPARG 833/4885CYP11B1 3114/4885CYP11B2 3394/4885
US-20240082207-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES CD68, PRNP, HTT PPARG 833/4885CYP11B1 3114/4885CYP11B2 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.